TCON (TRACON Pharmaceuticals) שווי פירמה כולל

TRACON Pharmaceuticals (TCON) is in a critical financial state, spending its remaining funds to wind down operations following the failure of clinical trials. This price chart reflects the company's current valuation at , whereas potential revenue was previously based on the exclusivity of drugs for rare tumors. The company is currently focusing on developing targeted sarcoma treatments for highly specialized clinics.

Enterprise Value determines the total cost of acquiring a business by summing market capitalization and net debt to reveal the actual costs of buying out all liabilities and shares. The current Enterprise Value assessment reflects the financial stability of TRACON Pharmaceuticals (TCON), illustrating how the biopharmaceutical platform's capitalization correlates with the costs of developing a closed-loop antibody development circuit for strategic partners.